Incanthera Competitors and Similar CompaniesClear all
G1 Therapeutics's competitors and similar companies include Alpine Immune Sciences and Oncolytics Biotech.
 G1 Therapeutics G1 Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. |  Alpine Immune Sciences Alpine Immune Sciences is a biotechnology company that develops protein-based immunotherapies. |  Oncolytics Biotech Oncolytics Biotech is a company developing Pelareorep, an intravenously delivered immuno-oncolytic virus, used for the treatment of solid tumors and hematological malignancies. | |
Founding Date | Founding Date 2008 | Founding Date 2015 | Founding Date 1998 |
Type | Type Public | Type Subsidiary | Type Public |
Tags | |||
Locations | Locations Durham, US HQ | Locations Seattle, US HQ | Locations Calgary, CA HQ Calgary, CA San Diego, US |
Employees | Employees 17015% increase | Employees 484% decrease | Employees 28 |
Valuation ($) | Valuation ($) 377.2 m | Valuation ($) N/A | Valuation ($) 93.9 m |
Financial | |||
Revenue (est.) | Revenue (est.) $82.5m (FY, 2023) | Revenue (est.) $58.9m (FY, 2023) | Revenue (est.) N/A |
Cost of goods | Cost of goods $7.2m (FY, 2023) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $75.3m (FY, 2023) | Gross profit N/A | Gross profit N/A |
Net income | Net income ($48m) (FY, 2023) | Net income ($32.2m) (FY, 2023) | Net income ($28.8m) (FY, 2025) |
Funding | |||
Total funding raised | Total funding raised $ 289.6m | Total funding raised $ 49.3m | Total funding raised $ 24m |
For sources of this data, please see the company profile
View Company Profiles
Alpine Immune Sciences
HQ
Seattle, US
Alpine Immune Sciences is a biotechnology company that develops protein-based immunotherapies.
View companyOncolytics Biotech
HQ
Calgary, CA
Employees
28
Oncolytics Biotech is a company developing Pelareorep, an intravenously delivered immuno-oncolytic virus, used for the treatment of solid tumors and hematological malignancies.
View company